ROME, AUG 19 - An Italo-US team of scientists have made a breakthrough in the early diagnosis of amyotrophic lateral ...

Summary: A new study has uncovered why some motor neurons resist degeneration in ALS while others succumb. Researchers found ...

Neurizon Therapeutics has reported positive topline results from an open-label extension (OLE) study of its lead candidate ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

Jodi O’Donnell-Ames founded Hope Loves Company to provide support, resources, and community to children affected by ALS.

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

Stanford University scientists have developed a brain implant designed to "hear" and vocalize words a person with severe ...

The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease predominantly affecting upper and lower motor neurons. Here, the authors outline previous and current efforts to characterize ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.